At the frontline of science
We have been committed to R&D from day one in order to offer the latest technology in computational drug discovery services, and to discover new methods and algorithms for data processing in biomedical research.
The main line of research of Mind the Byte is focused on the development of new techniques and algorithms to be used in our computer-aided drug development tools. We are determined to push the boundaries of computational chemistry and offer our customers the best-in-class solutions for their needs.
We are also active participants in European projects and consortia within the framework of Horizon 2020 (H2020) and the earlier Seventh Framework Programme (7PM), both of which play key roles in accelerating innovation and converting it into real solutions for the unresolved problems of many diseases. List of projects are are involved in:
Mind the Byte is one of the partners in the NOAH research program, slated to receive €2 million in funding over the next four years to develop therapies within the area of functional molecular containers, encapsulation processes and their applications.
NOAH is one of the projects funded by the Horizon 2020 ITN – ETN programme and will be executed between 2018 and 2022.
We are one of the partners in the Mechano-Control research project slated to receive €7 million in funding between 2017 and 2021 to develop therapies for cancer, fibrosis and other diseases.
The project will integrate experimental data with multi-scale computational modelling to establish the rules driving biological response to mechanics and adhesion.
Translink (2013-2018) is a project of the European Union Seventh Framework Programme that aims to determine the factors that lead to deterioration and failure in biological heart valve prostheses caused by an autoimmune response and to develop treatments to prevent these problems. Mind the Byte’s contribution to this project consists of the computational discovery and design (in silico) of new compounds that can take on antibodies related to prosthesis damage.
Industrial PhD programme
We are participating in the Government of Catalonia’s Industrial Doctorate Programme in conjunction with the University of Vic-Central University of Catalonia, the University of Barcelona, and the Polytechnic University of Catalonia, which promotes innovation and knowledge transfer between universities and the business world. Incorporating doctoral students into Mind the Byte’s bioinformatics team has allowed us to conduct new research projects like the development of extraordinarily innovative virtual screening methods for the pharmaceutical sector.
CM1407 (COST Action)
The COST Action Challenging Organic Syntheses Inspired by Nature from Natural Products Chemistry to Drug Discovery (2015-2019) seeks to make advances in the study of natural products (NP), which have had a significant impact on drug discovery and have been among the remedies used by physicians since ancient times. COST Action combines synthetic chemistry, computational chemistry, biological chemistry, and pharmacology to find new and relevant pharmaceutical structures for the treatment of cancer, cardiovascular disease, and bacterial and fungal infections.
NGP-net (COST Action)
The aim of the Non-globular Proteins COST Action is to create an effective European network, seeking synergy between participants towards joint activities, enabling the pooling of otherwise fragmented resources and uniting the voices of a large number of European labs, in the better understanding of overlapping phenomena concerning non-globular proteins (NGPs) and their joint consensus classification.
Datanimbus (SME Instrument)
DataNimbus is a commercial solution to transfer, store, share and analyse bioinformatic data from a single product. It aims to bring closer usually expensive and unaffordable data movement and processing technologies to European SME and research facilities.
StemChem (COST Action)
Another European project we worked on is COST Action Chemical Approaches to Targeting Drug Resistance in Cancer Stem Cells (2012-2016), which brought together researchers with experience in drug discovery and in the medicinal chemistry of synthetic and natural compounds, and researchers who study the mechanisms that govern the drug resistance of stem cells in cancer.
Stem cells play a key role in the failure of current cancer therapies. This means a completely new approach to drug development is needed. Sharing the experience and knowledge of groups of experts in chemistry and biology could very well lead to the creation of effective methods to identify new compounds and candidate drugs to target drug-resistant cancerous stem cells. Mind the Byte participated in the computational models workgroup.